LENZ

LENZ Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website lenz-tx.com
Employees(FY) -
ISIN US52635N1037

Performance

+6.01%

-5.83%

+47.78%

+78.11%

+89.23%

YTD

+116.5%

Profile

LENZ Therapeutics, Inc. develops ophthalmic pharmaceutical products. The company develops LNZ100 and LNZ101 which are aceclidine-based eye drops designed to correct the loss of near vision associated with presbyopia. The company develops eye drops that help restore the loss of near vision associated with presbyopia, enabling patients to get an on-demand, rapid-acting, and safe treatment option. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was incorporated in 2013 and is based in Del Mar, California.

Advanced Technical Analysis

Technical Analysis of LENZ 2024-12-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 70 indicating positive trend strength, while the Oscillators Score of 56 suggests a neutral momentum phase. The combined Technical Score of 63 reinforces the bullish outlook, signaling potential upward movement in the stock's price.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LENZ

Stock Rank

Recent News & Updates

2024-12-01 08:21
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely(Simply Wall St.)
2024-11-12 08:00
LENZ Therapeutics to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-11-11 19:00
LENZ Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-06 07:00
LENZ Therapeutics Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-05 18:00
LENZ Therapeutics Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-10-30 08:00
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024(GlobeNewswire)
2024-10-29 20:00
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024(Globenewswire)
2024-10-27 21:00
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100(GlobeNewswire)
2024-10-27 09:00
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100(Globenewswire)
2024-10-22 08:10
Lenz Therapeutics announces FDA acceptance of NDA for LNZ100(TipRanks)
2024-10-21 08:00
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia(GlobeNewswire)
2024-10-20 20:00
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia(Globenewswire)
2024-09-30 08:00
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences(GlobeNewswire)
2024-09-29 20:00
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences(Globenewswire)
2024-09-12 10:26
LENZ Therapeutics Insiders Up US$178k On US$551.1k Investment(Simply Wall St.)
2024-08-27 16:01
LENZ Therapeutics to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-08-27 04:01
LENZ Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-14 16:05
LENZ Therapeutics Reports Second Quarter 2024 Financial Results(GlobeNewswire)
2024-08-14 04:05
LENZ Therapeutics Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-12 08:00
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia(GlobeNewswire)
2024-08-11 20:00
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia(Globenewswire)
2024-08-07 16:01
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024(GlobeNewswire)
2024-08-07 04:01
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024(Globenewswire)
2024-07-15 08:00
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital(GlobeNewswire)
2024-07-14 20:00
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital(Globenewswire)
2024-06-23 10:12
We Think LENZ Therapeutics (NASDAQ:LENZ) Can Afford To Drive Business Growth(Simply Wall St.)
2024-06-10 08:00
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024(GlobeNewswire)
2024-06-09 20:00
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024(Globenewswire)
2024-05-30 08:00
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference(GlobeNewswire)
2024-05-29 20:00
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.